Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 14, 2019 - Issue
Submit an article Journal homepage
88
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD

Courtney Crim1 GSK, Research and Development, Research Triangle Park, NC, USA, [email protected]Correspondence[email protected]
,
Michael L Watkins1 GSK, Research and Development, Research Triangle Park, NC, USA, [email protected]
,
Eric D Bateman2 Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa
,
Gregory J Feldman3 S. Carolina Pharmaceutical Research, Spartanburg, SC, USA
,
Isabelle Schenkenberger4 Klinische Forschung Berlin GbR, Berlin, Germany
,
Edward M Kerwin5 Clinical Trials Division, Crisor LLC, Clinical Research Institute, Medford OR, USA
,
Catriona Crawford6 GSK, Global Medical, Stockley Park, Uxbridge, Middlesex, UK
,
Krishna Pudi7 Upstate Pharmaceutical Research, Greenville, SC, USA
,
Shuyen Ho8 PAREXEL International, Durham, NC, USA
,
Charlotte Baidoo9 GSK, Clinical Statistics, Stockley Park, Uxbridge, Middlesex, UK
&
Ramiro Castro-Santamaria10 GSK, Research and Development, Collegeville, PA, USA
 show all
Pages 615-629 | Published online: 08 Mar 2019

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Sabina Antonela Antoniu, Claudia Mariana Handra, Agripina Rascu, Bogdan Alexandru Barbu & Ioan Chirap Mitulschi. (2023) Navafenterol for chronic obstructive pulmonary disease therapy. Expert Opinion on Investigational Drugs 32:4, pages 283-290.
Read now
Josuel Ora, Angelo Coppola, Mario Cazzola, Luigino Calzetta & Paola Rogliani. (2020) Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease. Journal of Experimental Pharmacology 12, pages 559-574.
Read now
Robert M Burkes & Ralph J Panos. (2020) Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease. Journal of Experimental Pharmacology 12, pages 589-602.
Read now

Articles from other publishers (5)

Johannes Köckenberger, Oliver Fischer, Andreas Konopa, Sebastian Bergwinkl, Susanne Mühlich, Peter Gmeiner, Roger Jan Kutta, Harald Hübner, Max Keller & Markus R. Heinrich. (2022) Synthesis, Characterization, and Application of Muscarinergic M 3 Receptor Ligands Linked to Fluorescent Dyes . Journal of Medicinal Chemistry 65:24, pages 16494-16509.
Crossref
Mario Cazzola, Josuel Ora, Luigino Calzetta, Paola Rogliani & Maria Gabriella Matera. (2022) The future of inhalation therapy in chronic obstructive pulmonary disease. Current Research in Pharmacology and Drug Discovery 3, pages 100092.
Crossref
Dave Singh. 2022. Encyclopedia of Respiratory Medicine. Encyclopedia of Respiratory Medicine 741 753 .
Yingmin Liang & Judith C.W. Mak. (2021) Inhaled Therapies for Asthma and Chronic Obstructive Pulmonary Disease. Current Pharmaceutical Design 27:12, pages 1469-1481.
Crossref
Oliver Fischer, Josefa Hofmann, Hannelore Rampp, Jonas Kaindl, Gerald Pratsch, Amelie Bartuschat, R. Verena Taudte, Martin F. Fromm, Harald Hübner, Peter Gmeiner & Markus R. Heinrich. (2020) Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists. Journal of Medicinal Chemistry 63:8, pages 4349-4369.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.